ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE

BACKGROUND: Current therapies for recurrent glioblastoma provide limited survival benefit. In the open-label, phase 3 CheckMate 143 study (NCT02017717), although the primary endpoint was not met, the median overall survival (mOS) was comparable between nivolumab (anti–PD-1) and bevacizumab in the ov...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Weller, Michael, Reardon, David, Brandes, Alba, Sampson, John, Mulholland, Paul, Wick, Antje, Baehring, Joachim, Ahluwalia, Manmeet, Roth, Patrick, Bähr, Oliver, Phuphanich, Surasak, Sepulveda, Juan, de Souza, Paul, Sahebjam, Solmaz, Potter, Von, Tatsuoka, Kay, Taitt, Corina, Zwirtes, Ricardo, Omuro, Antonio, Lim, Michael
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Adult Clinical Trials–Immunologic
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847600/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.045
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料